News & Updates
Showing Infectious Diseases articles
Showing

Fluvoxamine improves fatigue, QoL in long COVID patients
Patients with long COVID may derive benefits from treatment with fluvoxamine, which has been shown to reduce fatigue and improve quality of life (QoL) in a study. The use of metformin, on the other hand, shows no significant advantage.
Fluvoxamine improves fatigue, QoL in long COVID patients
19 Apr 2026
Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable
Post-exposure prophylaxis-in-pocket (PIP) appears as effective as pre-exposure prophylaxis (PrEP) in improving quality of life (QoL) of individuals at low risk for HIV but may be a less costly option, according to a matched-control study presented at CROI 2026.
Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable
17 Apr 2026
Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients
Genetic markers, both in and outside the immune system, influence an individual’s response to the SARS-CoV-2 vaccine, and these effects are similar in patients with or without systemic autoimmune diseases (SADs), reports a study.
Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients
11 Apr 2026
CKD patients more prone to tuberculosis
Patients with stage 5 chronic kidney disease (CKD5) are at greater risk of developing tuberculosis (TB) than the general population, especially if they are male or receiving dialysis, suggests a Singapore study.
CKD patients more prone to tuberculosis
30 Mar 2026
Antibiotics, low-yield investigations for recurrent UTI prevail in real-world practice
Recurrent urinary tract infection (UTI) care in primary and secondary care settings appears to be characterized by low guideline adherence, with a substantial number of women still being treated with antibiotics and subjected to low-yield investigations, according to a study.
Antibiotics, low-yield investigations for recurrent UTI prevail in real-world practice
29 Mar 2026
IPF drug extends benefit in post-COVID-19 lung injuries
A meta-analysis has shown the efficacy of the antifibrotic agent pirfenidone in preventing the onset and/or progression of interstitial lung abnormalities (ILAs) caused by COVID-19.



